Johnson & Johnson last reported quarterly results on Oct 13, 2026, for Q3 FY2026 (the quarter ended Sep 27, 2026): revenue of $25.4 billion (+5.9% year over year) and diluted EPS of $0.09. It usually reports 16–24 days after a quarter ends. Based on that pattern, the next release is estimated for around Jan 20, 2027.
Results for Q4 FY2026, the quarter ending around Dec 27, 2026. Expected on a Wednesday. Based on last year's release for the same quarter on Jan 21, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 16–24 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Oct 13, 2026
16 days after quarter end
|
Q3 FY2026
ended Sep 27, 2026
|
25,399
+5.9%
|
210
-95.9%
|
0.09
-95.8%
|
|
Jul 15, 2026
17 days after quarter end
|
Q2 FY2026
ended Jun 28, 2026
|
25,310
+6.6%
|
5,534
-0.1%
|
2.27
-0.9%
|
|
Apr 14, 2026
16 days after quarter end
|
Q1 FY2026
ended Mar 29, 2026
|
24,062
+9.9%
|
5,235
-52.4%
|
2.14
-52.9%
|
|
Jan 21, 2026
24 days after quarter end
|
Q4 FY2025
ended Dec 28, 2025
|
24,564
+9.1%
|
5,116
+49.1%
|
2.09
+48.3%
|
|
Oct 14, 2025
16 days after quarter end
|
Q3 FY2025
ended Sep 28, 2025
|
23,993
+6.8%
|
5,152
+91.2%
|
2.12
+91.0%
|
|
Jul 16, 2025
17 days after quarter end
|
Q2 FY2025
ended Jun 29, 2025
|
23,743
+5.8%
|
5,537
+18.2%
|
2.29
+18.7%
|
|
Apr 15, 2025
16 days after quarter end
|
Q1 FY2025
ended Mar 30, 2025
|
21,893
+2.4%
|
10,999
+237.9%
|
4.54
+238.8%
|
|
Jan 22, 2025
24 days after quarter end
|
Q4 FY2024
ended Dec 29, 2024
|
22,520
+5.3%
|
3,431
-15.3%
|
1.41
-15.4%
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- JNJ (NYSE)
- Fiscal year ends
- January 3
- Incorporated in
- NJ
- Headquarters
- New Brunswick, NJ
- SEC filer status
- Large accelerated filer
- SEC CIK
- 200406
- Former names
- JOHNSON & JOHNSON ET AL (until Jan 23, 1996)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
- Pfizer Inc PFE
Source: SEC EDGAR filings. This is company-reported data, not investment advice.